Results 1 to 10 of about 29,905 (235)

Optimal Medical Therapy Versus Septal Reduction Therapy [PDF]

JACC: Advances
[Figure: see text]
Francis Joshua Beloy, MD MBA, Jillian Reeze Medina, MD, Ralf Martz Sulague, MD MS, Jacques Kpodonu, MD   +3 more
doaj   +7 more sources

The Risk of Ventricular Arrhythmias between Alcohol Septal Ablation and Septal Myectomy in Hypertrophic Cardiomyopathy: A Meta-Analysis on Septal Reduction Therapy [PDF]

Reviews in Cardiovascular Medicine, 2022
Background: Alcohol septal ablation (ASA) has been more commonly applied in medical refractory hypertrophic obstructive cardiomyopathy (HOCM) compared with septal myectomy (SM), however its potential to create a proarrhythmic substrate is increased ...
Wei Tang, Menghui Liu, Jie Li, Rongxuan Chang, Chen Su, Xiaoyu Zhang, Lichun Wang   +6 more
doaj   +6 more sources

Alcohol Septal Ablation or Septal Myectomy? An Updated Systematic Review and Meta-Analysis of Septal Reduction Therapy for Hypertrophic Obstructive Cardiomyopathy [PDF]

Frontiers in Cardiovascular Medicine, 2022
ObjectiveTo evaluate the safety and effectiveness of alcohol septal ablation (ASA) and septal myectomy (SM) for the treatment of hypertrophic obstructive cardiomyopathy.MethodsWe searched the PubMed, MEDLINE, EMBASE, and CBM databases for observational ...
Xifeng Zheng, Bin Yang, Haosheng Hui, Bing Lu, Yinhui Feng   +4 more
doaj   +6 more sources

Septal Reduction Therapy for Obstructive Hypertrophic Cardiomyopathy: Volume Still Matters for Septal Myectomy [PDF]

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2023
Vincent Y. See, Libin Wang
doaj   +6 more sources

Hospital Procedural Volume and Clinical Outcomes Following Septal Reduction Therapy in Obstructive Hypertrophic Cardiomyopathy [PDF]

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2023
Background Prior national data showed a substantial in‐hospital mortality in septal myectomy (SM) with an inverse volume–outcomes relationship. This study sought to assess the contemporary outcomes of septal reduction therapy and volume–outcome ...
Ahmed M. Altibi, Fares Ghanem, Yuanzi Zhao, Miriam Elman, Joaquin Cigarroa, Babak Nazer, Howard K. Song, Ahmad Masri   +7 more
doaj   +4 more sources

Access Challenges for Septal Reduction Therapy Among Individuals With Obstructive Hypertrophic Cardiomyopathy [PDF]

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background In symptomatic patients with treatment‐refractory obstructive hypertrophic cardiomyopathy, septal reduction therapy (SRT) is recommended to relieve obstruction. This study examined the challenges associated with SRT access in the United States.
Anjali T. Owens, Patricia Schuler, Jenny Jiang, Xu Han, Ervant Maksabedian Hernandez, Amy Anderson, Yiyu Fang, Andrea Steffens, Anandkumar Dubey   +8 more
doaj   +4 more sources

Emerging technologies for septal reduction therapy in hypertrophic cardiomyopathy [PDF]

Chinese Medical Journal
Yunye Zhang, Xingwei Zhang, Zhihong Zhao, Rongman Jia   +3 more
doaj   +5 more sources

Impact of Mavacamten Approval on Septal Reduction Therapy Rates in Hypertrophic Cardiomyopathy [PDF]

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Ramzi Ibrahim, Winston Wang, Hoang Nhat Pham, Mahmoud Abdelnabi, Steven J. Lester, Susan Wilansky, Hartzell V. Schaff, Jeffrey B. Geske, Reza Arsanjani, Chadi Ayoub   +9 more
doaj   +4 more sources

Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy

Journal of the American College of Cardiology, 2022
Septal reduction therapy (SRT), surgical myectomy or alcohol ablation, is recommended for obstructive hypertrophic cardiomyopathy (oHCM) patients with intractable symptoms despite maximal medical therapy, but is associated with morbidity and mortality.This study sought to determine whether the oral myosin inhibitor mavacamten enables patients to ...
Anjali Tiku Owens, Milind Desai, Hartzell Schaff   +2 more
exaly   +3 more sources

Interventions for Hypertrophic Obstructive Cardiomyopathy: Defining the Gold Standard, Assessing Durability, and Guiding Patient Selection [PDF]

Medical Sciences
Hypertrophic obstructive cardiomyopathy (HOCM) is a genetic disorder characterized by a dynamic left ventricular outflow tract (LVOT) obstruction and an increased risk of sudden cardiac death.
Ajibola Anifowose, Marco Tagliafierro, Ghadeer Mahdi, Saada Hussein, Massimo Baudo, Tulio Caldonazo, Aleksander Dokollari, Kaveh Hosseini, William D. T. Kent, Ali Fatehi Hassanabad   +9 more
doaj   +2 more sources